FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040821387> ?p ?o ?g. }

• W2040821387 endingPage "111" @default.
• W2040821387 startingPage "109" @default.
• W2040821387 abstract "In this issue of the AJRCCM (pp. 105–108), there is an interesting These attributes—demonstrated efficacy in promoting wakePro/Con debate about whether the drug modafinil (Provigil) has fulness, limited and not serious side effects, and lack of abuse a role (1), or not (2), in the management of obstructive sleep potential—suggest that modafinil will be an extremely useful apnea. This is an important debate and the pros and cons are medication. But what will its role be? well laid out by Black (1) and Pollak (2). The current issues Originally, modafinil was approved by the FDA for the treatabout use of modafinil, however, include more than its role in ment of narcolepsy on the basis of expensive multicenter studies sleep apnea. At present it is being proposed that the Food and conducted by its manufacturer, Cephalon (7). Narcolepsy is a Drug Administration (FDA) approve modafinil for the broad life-long condition that usually starts in the teen years or in indication of excessive daytime sleepiness. This raises some intersubjects in their 20s and results in marked excessive sleepiness esting medical dilemmas that are the subject of this essay. (for review, see Overeem and coworkers [11]). It does not, howModafinil is different from previous medications used for wake ever, have a particularly high prevalence, being on the order of promotion, that is, amphetamines and their derivatives. Modafi1 in 2,000 (11). Modafinil has quickly become the drug of choice nil lacks abuse potential (3, 4). There are also major differences for management of sleepiness in narcolepsy. in recovery sleep that follows a period after an animal has been Although modafinil is acceptable for narcolepsy, the current kept awake for prolonged periods by a pharmacologic agent. question concerns whether there are other indications for its With amphetamines, the pressure for sleep (sleep homeostasis) use. This is a subject of considerable media interest, with articles builds up during the induced period of prolonged wakefulness. in The New Yorker and elsewhere, and stories on major national Hence, when amphetamines are stopped, profound amounts of media outlets, such as CNN. The media attention has presumably deep, slow-wave sleep are observed (5, 6). In contrast, when contributed to the already widespread off-label use of modafinil similar studies are done with modafinil, there is limited sleep in the United States, beyond the prevalence of the approved recovery when modafinil is stopped (5, 6). This has led to the indication for narcolepsy. As reported by the Washington Post suggestion that modafinil is somnolytic, and that it must act (12), this media attention led the FDA to write to Cephalon directly to block the sleep-promoting system. in January 2002, warning the company about its promotional Modafinil is a safe compound with only minor side effects materials. The FDA noted that “Provigil is not approved to treat such as headache, which is often transient at initiation of therapy such symptoms as sleepiness, tiredness, decreased activity, lack (7–10). It has been used in France, where it was discovered, for of energy and fatigue.” many years and long-term studies of use reveal a favorable sideAt present, on the basis of studies such as those on patients effect profile (8). with obstructive sleep apnea with residual sleepiness, who were effectively being treated with nasal continuous positive airway pressure (CPAP) (9, 10, 13), the potential role of modafinil in other conditions is being considered. Interestingly, regulatory" @default.
• W2040821387 created "2016-06-24" @default.
• W2040821387 creator A5001740246 @default.
• W2040821387 date "2003-01-15" @default.
• W2040821387 modified "2023-09-27" @default.
• W2040821387 title "Should a Pharmaceutical Be Approved for the Broad Indication of Excessive Sleepiness?" @default.
• W2040821387 cites W1788205751 @default.
• W2040821387 cites W1819447783 @default.
• W2040821387 cites W1826693785 @default.
• W2040821387 cites W1831987699 @default.
• W2040821387 cites W1832042843 @default.
• W2040821387 cites W1855097856 @default.
• W2040821387 cites W1887439240 @default.
• W2040821387 cites W1911820154 @default.
• W2040821387 cites W1977426271 @default.
• W2040821387 cites W1979925785 @default.
• W2040821387 cites W1994379541 @default.
• W2040821387 cites W1994381724 @default.
• W2040821387 cites W1997274278 @default.
• W2040821387 cites W2007954852 @default.
• W2040821387 cites W2018225738 @default.
• W2040821387 cites W2037464054 @default.
• W2040821387 cites W2040480454 @default.
• W2040821387 cites W2042152853 @default.
• W2040821387 cites W2051125346 @default.
• W2040821387 cites W2063135200 @default.
• W2040821387 cites W2075726900 @default.
• W2040821387 cites W2087045789 @default.
• W2040821387 cites W2114942155 @default.
• W2040821387 cites W2115730526 @default.
• W2040821387 cites W2128103058 @default.
• W2040821387 cites W2134610731 @default.
• W2040821387 cites W2136654722 @default.
• W2040821387 cites W2139704316 @default.
• W2040821387 cites W2139826323 @default.
• W2040821387 cites W2141493724 @default.
• W2040821387 cites W2164270771 @default.
• W2040821387 cites W2325992678 @default.
• W2040821387 cites W2335449614 @default.
• W2040821387 cites W2413815627 @default.
• W2040821387 doi "https://doi.org/10.1164/rccm.2211007" @default.
• W2040821387 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12524251" @default.
• W2040821387 hasPublicationYear "2003" @default.
• W2040821387 type Work @default.
• W2040821387 sameAs 2040821387 @default.
• W2040821387 citedByCount "14" @default.
• W2040821387 countsByYear W20408213872016 @default.
• W2040821387 crossrefType "journal-article" @default.
• W2040821387 hasAuthorship W2040821387A5001740246 @default.
• W2040821387 hasConcept C177713679 @default.
• W2040821387 hasConcept C71924100 @default.
• W2040821387 hasConceptScore W2040821387C177713679 @default.
• W2040821387 hasConceptScore W2040821387C71924100 @default.
• W2040821387 hasIssue "2" @default.
• W2040821387 hasLocation W20408213871 @default.
• W2040821387 hasLocation W20408213872 @default.
• W2040821387 hasOpenAccess W2040821387 @default.
• W2040821387 hasPrimaryLocation W20408213871 @default.
• W2040821387 hasRelatedWork W1506200166 @default.
• W2040821387 hasRelatedWork W2039318446 @default.
• W2040821387 hasRelatedWork W2048182022 @default.
• W2040821387 hasRelatedWork W2080531066 @default.
• W2040821387 hasRelatedWork W2604872355 @default.
• W2040821387 hasRelatedWork W2748952813 @default.
• W2040821387 hasRelatedWork W2899084033 @default.
• W2040821387 hasRelatedWork W3032375762 @default.
• W2040821387 hasRelatedWork W3108674512 @default.
• W2040821387 hasRelatedWork W4252371801 @default.
• W2040821387 hasVolume "167" @default.
• W2040821387 isParatext "false" @default.
• W2040821387 isRetracted "false" @default.
• W2040821387 magId "2040821387" @default.
• W2040821387 workType "article" @default.